Mylan Hungary's Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan's expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the extremely low health literacy rates in the country.
As an introduction to our readers could you please provide some insight into your rather non-traditional background and describe a few of the factors that ultimately lead you to Mylan and any difficulties you encountered during your transition?
For me, the right approach is not to oppose innovative medicines versus generics as I believe there is a symbiosis between the two. This symbiosis allows innovators to utilize their patent, and generics to help expand access in the market.
